Literature DB >> 19067393

Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.

Abhishek Gulati1, Phillip M Gerk.   

Abstract

Highly active anti-retroviral therapy (HAART) is used to treat HIV-infected patients and involves administration of multiple antiretroviral drugs acting at different steps of the HIV life cycle. In treating HIV-infected pregnant patients, the aim of therapy is not only to treat the mother but also to prevent the transmission of the virus to the fetus. Among the antiretroviral drugs used, there are differences in the extent of transfer of these drugs across the placenta; HIV protease inhibitors are particularly poorly transferred. Activities of ABC transporters expressed in the human placenta as well as differences in plasma protein binding may account for the poor transplacental transfer of certain drugs. This review discusses factors affecting the extent of placental transfer of antiretroviral drugs during pregnancy. These issues may also apply to drugs in other therapeutic categories.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067393      PMCID: PMC2895503          DOI: 10.1002/jps.21623

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  99 in total

1.  Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Authors:  J W Smit; M T Huisman; O van Tellingen; H R Wiltshire; A H Schinkel
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.

Authors:  P Langmann; M Zilly; B Weissbrich; C Schlör; T Väth; E Richter; H Klinker
Journal:  Eur J Med Res       Date:  2000-02-28       Impact factor: 2.175

3.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

Authors:  M Brangi; T Litman; M Ciotti; K Nishiyama; G Kohlhagen; C Takimoto; R Robey; Y Pommier; T Fojo; S E Bates
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

4.  Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.

Authors:  Sreeja Sudhakaran; Craig R Rayner; Jian Li; David C M Kong; Neil M Gude; Roger L Nation
Journal:  Br J Clin Pharmacol       Date:  2007-12-17       Impact factor: 4.335

Review 5.  Antiepileptic medication during pregnancy: does fetal genotype affect outcome?

Authors:  Diane E Atkinson; Sophie Brice-Bennett; Stephen W D'Souza
Journal:  Pediatr Res       Date:  2007-08       Impact factor: 3.756

6.  Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.

Authors:  Caroline Solas; Nicolas Simon; Marie-Pierre Drogoul; Sylvie Quaranta; Véronique Frixon-Marin; Véronique Bourgarel-Rey; Corinne Brunet; Jean-Albert Gastaut; Alain Durand; Bruno Lacarelle; Isabelle Poizot-Martin
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

7.  Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.

Authors:  Honggang Wang; Eun-Woo Lee; Lin Zhou; Peter C K Leung; Douglas D Ross; Jashvant D Unadkat; Qingcheng Mao
Journal:  Mol Pharmacol       Date:  2007-11-27       Impact factor: 4.436

8.  Breast cancer resistance protein (Bcrp1/Abcg2) in mouse placenta and yolk sac: ontogeny and its regulation by progesterone.

Authors:  G M Kalabis; S Petropoulos; W Gibb; S G Matthews
Journal:  Placenta       Date:  2007-05-24       Impact factor: 3.481

9.  Hormonal regulation of BCRP expression in human placental BeWo cells.

Authors:  Honggang Wang; Jashvant D Unadkat; Qingcheng Mao
Journal:  Pharm Res       Date:  2007-09-06       Impact factor: 4.580

Review 10.  BCRP/ABCG2 in the placenta: expression, function and regulation.

Authors:  Qingcheng Mao
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

View more
  9 in total

1.  Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.

Authors:  J B Pain; M P Lê; M Caseris; C Amiel; L Lassel; C Charpentier; A Desnoyer; C Farnoux; G Pialoux; D Descamps; G Peytavin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.

Authors:  Sarah K Himes; Julia W Wu; Denise L Jacobson; Katherine Tassiopoulos; Rohan Hazra; Deborah Kacanek; Russell B Van Dyke; Kenneth C Rich; George K Siberry; Marilyn A Huestis
Journal:  Pediatr Infect Dis J       Date:  2015-08       Impact factor: 2.129

Review 3.  ATP-binding cassette efflux transporters in human placenta.

Authors:  Zhanglin Ni; Qingcheng Mao
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

Review 4.  Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?

Authors:  Vera E Bukkems; Angela Colbers; Catia Marzolini; Jose Molto; David M Burger
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

5.  Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells.

Authors:  Tomohiro Nabekura; Tatsuya Kawasaki; Yuki Kamiya; Yuichi Uwai
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

6.  Clinical therapeutics in pregnancy.

Authors:  Maisa N Feghali; Donald R Mattison
Journal:  J Biomed Biotechnol       Date:  2011-07-06

7.  The Role of PXR Genotype and Transporter Expression in the Placental Transport of Lopinavir in Mice.

Authors:  Sarabjit S Gahir; Micheline Piquette-Miller
Journal:  Pharmaceutics       Date:  2017-10-24       Impact factor: 6.321

Review 8.  Chemotherapy Resistance Explained through Endoplasmic Reticulum Stress-Dependent Signaling.

Authors:  Entaz Bahar; Ji-Ye Kim; Hyonok Yoon
Journal:  Cancers (Basel)       Date:  2019-03-08       Impact factor: 6.639

9.  Fetal Membranes Contribute to Drug Transport across the Feto-Maternal Interface Utilizing the Breast Cancer Resistance Protein (BCRP).

Authors:  Ananthkumar Kammala; Meagan Benson; Esha Ganguly; Enkhtuya Radnaa; Talar Kechichian; Lauren Richardson; Ramkumar Menon
Journal:  Life (Basel)       Date:  2022-01-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.